A peptide ETA receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

BQ-123

Item No. 19153

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
cyclo(D-α-aspartyl-L-prolyl-D-valyl-L-leucyl-D-tryptophyl)
CAS Number
136553-81-6
Synonyms
  • Cyclo(D-Trp-D-Asp-Pro-D-Val-Leu)
Molecular Formula
C31H42N6O7
Formula Weight
610.7
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 20 mg/mlDMSO:PBS (pH 7.2) (1:2): 0.33 mg/mlPBS (pH 7.2): slightly
λmax
221 nm
SMILES
O=C([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC(C)C)NC([C@@H](C(C)C)N3)=O)=O)N[C@]([H])(CC(O)=O)C(N4CCC[C@]4(C3=O)[H])=O
InChi Code
InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-
InChi Key
VYCMAAOURFJIHD-PJNXIOHISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $117

    Add

    5 mg

    $484

    Add

    10 mg

    $909

    Add
    Product Description

    BQ-123 is a peptide endothelin type A (ETA) receptor antagonist (IC50 = 7.3 nM).1 It is selective for ETA over ETB receptors (Kis = 0.025 and 31 µM, respectively).2 BQ-123 inhibits growth of human pulmonary artery smooth muscle cells induced by endothelin-1 (ET-1; Item No. 24127).3 It reverses ET-1-induced increases in mean arterial pressure (MAP) in rats.4 BQ-123 (3 mg/kg, i.v.) also delays seizure onset and reduces the number of rats with major seizures in a model of epilepsy induced by pentylenetetrazole (PTZ; Item No. 18682).5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ihara, M., Noguchi, K., Saeki, T., et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 50(4), 247-255 (1992).

    2. Sakamoto, A., Yanagisawa, M., Sawamura, T., et al. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. The Journal of Biological Chemisty 268(12), 8547-8553 (1993).

    3. Zamora, M.A., Dempsey, E.C., Walchak, S.J., et al. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 9(4), 429-433 (1993).

    4. Warner, T.D., Allcock, G.H., and Vane, J.R. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br. J. Pharmacol. 112(1), 207-213 (1994).

    5. Erdogan, H., Ekici, F., Katar, M., et al. The protective effects of endothelin-A receptor antagonist BQ-123 in pentylenetetrazole-induced seizure in rats. Hum. Exp. Toxicol. 33(10), 1008-1016 (2014).